Pulmonx Statistics
Total Valuation
Pulmonx has a market cap or net worth of $242.85 million. The enterprise value is $190.88 million.
Important Dates
The next estimated earnings date is Wednesday, February 19, 2025, after market close.
| Earnings Date | Feb 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pulmonx has 39.49 million shares outstanding. The number of shares has increased by 2.88% in one year.
| Current Share Class | 39.49M |
| Shares Outstanding | 39.49M |
| Shares Change (YoY) | +2.88% |
| Shares Change (QoQ) | +0.86% |
| Owned by Insiders (%) | 4.22% |
| Owned by Institutions (%) | 90.48% |
| Float | 37.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.01 |
| Forward PS | 2.55 |
| PB Ratio | 2.59 |
| P/TBV Ratio | 2.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.70, with a Debt / Equity ratio of 0.59.
| Current Ratio | 7.70 |
| Quick Ratio | 6.56 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.82 |
Financial Efficiency
Return on equity (ROE) is -51.99% and return on invested capital (ROIC) is -22.23%.
| Return on Equity (ROE) | -51.99% |
| Return on Assets (ROA) | -20.04% |
| Return on Capital (ROIC) | -22.23% |
| Revenue Per Employee | $284,237 |
| Profits Per Employee | -$204,685 |
| Employee Count | 279 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 1.24 |
Taxes
In the past 12 months, Pulmonx has paid $710,000 in taxes.
| Income Tax | 710,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.92% in the last 52 weeks. The beta is 0.69, so Pulmonx's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | -49.92% |
| 50-Day Moving Average | 6.51 |
| 200-Day Moving Average | 7.33 |
| Relative Strength Index (RSI) | 45.22 |
| Average Volume (20 Days) | 252,858 |
Short Selling Information
The latest short interest is 815,603, so 2.07% of the outstanding shares have been sold short.
| Short Interest | 815,603 |
| Short Previous Month | 842,687 |
| Short % of Shares Out | 2.07% |
| Short % of Float | 2.16% |
| Short Ratio (days to cover) | 3.62 |
Income Statement
In the last 12 months, Pulmonx had revenue of $79.30 million and -$57.11 million in losses. Loss per share was -$1.47.
| Revenue | 79.30M |
| Gross Profit | 58.81M |
| Operating Income | -56.49M |
| Pretax Income | -57.29M |
| Net Income | -57.11M |
| EBITDA | -55.00M |
| EBIT | -56.49M |
| Loss Per Share | -$1.47 |
Full Income StatementBalance Sheet
The company has $107.78 million in cash and $55.81 million in debt, giving a net cash position of $51.97 million or $1.32 per share.
| Cash & Cash Equivalents | 107.78M |
| Total Debt | 55.81M |
| Net Cash | 51.97M |
| Net Cash Per Share | $1.32 |
| Equity (Book Value) | 93.93M |
| Book Value Per Share | 2.38 |
| Working Capital | 122.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.26 million and capital expenditures -$1.54 million, giving a free cash flow of -$34.79 million.
| Operating Cash Flow | -33.26M |
| Capital Expenditures | -1.54M |
| Free Cash Flow | -34.79M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
Gross margin is 74.16%, with operating and profit margins of -71.23% and -72.01%.
| Gross Margin | 74.16% |
| Operating Margin | -71.23% |
| Pretax Margin | -71.12% |
| Profit Margin | -72.01% |
| EBITDA Margin | -69.36% |
| EBIT Margin | -71.23% |
| FCF Margin | n/a |
Dividends & Yields
Pulmonx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.88% |
| Shareholder Yield | -2.88% |
| Earnings Yield | -23.52% |
| FCF Yield | -14.33% |
Analyst Forecast
The average price target for Pulmonx is $11.92, which is 93.82% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.92 |
| Price Target Difference | 93.82% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 18.54% |
| EPS Growth Forecast (5Y) | -21.77% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pulmonx has an Altman Z-Score of -0.65 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.65 |
| Piotroski F-Score | 5 |